Histogen Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Histogen has a total shareholder equity of $4.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $5.8M and $1.4M respectively.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$4.57m
Eşitlik	US$4.40m
Toplam yükümlülükler	US$1.41m
Toplam varlıklar	US$5.82m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: HSTO's short term assets ($5.5M) exceed its short term liabilities ($1.3M).

Uzun Vadeli Yükümlülükler: HSTO's short term assets ($5.5M) exceed its long term liabilities ($65.0K).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: HSTO is debt free.

Borcun Azaltılması: HSTO has no debt compared to 5 years ago when its debt to equity ratio was 61.3%.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Insufficient data to determine if HSTO has enough cash runway based on its current free cash flow.

Tahmini Nakit Akışı: Insufficient data to determine if HSTO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Histogen Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Histogen Inc. Filed for Bankruptcy

Histogen Inc. Files Form 15

Nasdaq To File A Form 25-NSE with the SEC, To Remove Histogen's Securities from Listing and Registration

Histogen Intends to File Certificate of Dissolution, Delist its Shares of Common Stock from The Nasdaq Capital Market

Histogen Receives Letter from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(a)(2)

Histogen Announces 1-for-20 Reverse Stock Split

Recent updates

Histogen Inc. Filed for Bankruptcy

Histogen Inc. Files Form 15

Histogen Inc.(OTCPK:HSTO) dropped from NASDAQ Composite Index

Nasdaq To File A Form 25-NSE with the SEC, To Remove Histogen's Securities from Listing and Registration

Histogen Inc.(NasdaqCM:HSTO) dropped from S&P TMI Index

Histogen Inc. Announces Executive Changes

Histogen Intends to File Certificate of Dissolution, Delist its Shares of Common Stock from The Nasdaq Capital Market

Histogen Receives Letter from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(a)(2)

Histogen Inc. Hires Alfred P. Spada as Chief Scientific Officer

Histogen stock down 8% after Q2 loss, on track for six-day losing streak

Histogen Inc. to Report Q2, 2022 Results on Aug 11, 2022

Histogen Inc. announced that it expects to receive $5 million in funding

Histogen announces pricing of $5M private placement

Histogen Announces 1-for-20 Reverse Stock Split

First quarter 2022 earnings released: US$0.013 loss per share (vs US$0.14 loss in 1Q 2021)

Price target decreased to US$2.25

Histogen Inc., Annual General Meeting, Jun 01, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Histogen Inc. to Report Q4, 2021 Results on Mar 10, 2022

Histogen Not Regained Compliance with the Minimum Bid Price Requirement

Histogen Inc. announced that it has received $3.500001 million in funding

Histogen Inc. announced that it expects to receive $3.500001 million in funding

We're A Little Worried About Histogen's (NASDAQ:HSTO) Cash Burn Rate

Histogen Announces Initiation of HST 003 Phase 1/2 Trial for Knee Cartilage Regeneration

Histogen Inc. and its partner Amerimmune LLC Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients

Histogen jumps 11% after Intracoastal Capital reports 5.6% stake

Histogen Inc. has completed a Follow-on Equity Offering in the amount of $6.57503 million.

Histogen enters $6.5M at-the-market direct offering

Histogen Provides Update on its Development Programs and Pipeline Focus

Histogen and Amerimmune Reports Publication on Emricasan in COVID-19

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.55 loss in 1Q 2020)

Histogen Provides Business Update

Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic Covid-19 Patients

Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND to Initiate a Phase 1/2 Trial for Knee Cartilage Regeneration

Full year 2020 earnings released: US$2.08 loss per share (vs US$0.89 loss in FY 2019)

Histogen Inc. Announces Board Changes

Independent Director has left the company

Histogen Inc. to Report Q4, 2020 Results on Mar 11, 2021

Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

New 90-day high: US$1.72

Histogen Inc. Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration

Histogen Inc. has completed a Follow-on Equity Offering in the amount of $14 million.

Histogen under pressure on pricing $14M upsized public offering

Histogen Inc. Announces Filing an Investigational New Drug Application for HST-003

New 90-day low: US$1.19

Histogen files IND application for regenerative human matrix

Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

New 90-day low: US$1.31

Histogen soars after HST-001 data in male pattern baldness

Histogen Inc. has completed a Follow-on Equity Offering in the amount of $4.500016 million.

Histogen Inc. to Report Q3, 2020 Results on Nov 12, 2020

Histogen Inc. and Amerimmune Llc Enters into A Collaborative Development and Commercialization Agreement for Emricasan in the Treatment of Covid-19

Histogen Inc. Appoints Moya Daniels as Executive Vice President and Head of Regulatory, Quality and Clinical Operations

Histogen Announces Completion of Final Dosing Timepoint Milestone in its 1b/2a Trial for Androgenic Alopecia in Men

Histogen Announces Update for its HST-002 Dermal Filler Program

Histogen Inc. Announces Phase 1/2 Clinical Trial Designed to Evaluate HST-003

New 90-day low - US$1.64

First half earnings released

Histogen Inc. to Report Q2, 2020 Results on Aug 13, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin